TUDCA and Traumatic Brain Injury: What the Animal Research Shows
TUDCA reduced brain lesions and inflammation in rodent brain injury models, but one TBI study was retracted and no human trial exists.
TUDCA reduced brain lesions and inflammation in rodent brain injury models, but one TBI study was retracted and no human trial exists.
TUDCA lowered blood pressure in several rat and mouse models of hypertension. No human trial has measured blood pressure, and two small vessel studies split.
A 150-patient randomised trial cut liver enzymes on TUDCA. A Cochrane review of 27 trials found no effect on the virus and worse histology scores.
One of the few human trials of TUDCA itself tested it in infants on parenteral nutrition and found no effect. Why it failed is the useful part.
TUDCA preserved vision in diabetic mice, but only when started early. The human data measure bile acids in blood and give nobody TUDCA. What that means.
TUDCA has been given to human patients in registered amyloidosis trials, paired with prescription doxycycline. This is the clearest case of TUDCA’s chaperone activity being tested in people, and also the clearest case of why it is not a supplement protocol.
A bile acid cut infarct size roughly in half in a rat stroke model. That was 2002. Two decades later there is still no human stroke trial. Here is what the research showed and why the gap matters.
PBC is the one condition where TUDCA has been tested head-to-head against standard-of-care UDCA in a randomized trial. Here is what those human studies found, and why that does not make TUDCA a substitute for prescription treatment.
TUDCA and alcohol: what cell studies, bile acid research in alcoholic hepatitis, and TUDCA’s liver trial data actually show — and don’t show.
TUDCA is a naturally occurring bile acid studied for liver protection, neurological health, and metabolic support. Learn what it is, how it works, and what the
TUDCA and phosphatidylcholine protect the liver through distinct mechanisms. Compare their proposed actions, evidence base, and practical differences here.
A review of preclinical evidence on TUDCA and photoreceptor protection in retinal degeneration, including proposed mechanisms and animal model findings.